Second malignancy in patients with Hodgkin's disease treated at the Royal Marsden Hospital

British Journal of Cancer

Volumn 75, Issue 1, 1997, Pages 116-123

  Swerdlow, A J ^a   Barber, J A ^a   Horwich, A ^b   Cunningham, D ^b   Milan, S ^b   Omar, R Z ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Hodgkin's disease; Second malignancy

Indexed keywords

ALKYLATING AGENT; CHLORAMBUCIL; PREDNISONE; PROCARBAZINE; VINBLASTINE;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CHILD; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; LEUKEMIA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; NONHODGKIN LYMPHOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SECOND CANCER; SKIN CANCER; SOFT TISSUE CANCER; STOMACH CANCER;

EID: 0031022080     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.19     Document Type: Article

References (27)

1. Abrahamsen JF, Andersen A, Hannisdal E, Nome O, Abrahamsen AF, Kvaløy S and Høst H (1993) Second malignancies after treatment of Hodgkin's disease: the influence of treatment, follow-up time, and age. J Clin Oncol 11: 255-261
2. Biti G, Cellai E, Magrini SM, Papi MG, Ponticelli P and Boddi V (1994) Second solid tumors and leukemia after treatment for Hodgkin's disease: an analysis of 1121 patients from a single institution. Int J Radiation Oncol Biol Phys 29: 25-31
3. Boivin J-F and O'Brien K (1988) Solid cancer risk after treatment of Hodgkin's disease. Cancer 61: 2541-2546
4. Boivin J-F, Hutchison GB, Zauber AG, Bernstein L, Davis FG, Michel RP, Zanke B, Tan CTC, Fuller LM, Mauch P and Ultman JE (1995) Incidence of second cancers in patients treated for Hodgkin's disease. J Natl Cancer Inst 87: 732-741
5. Clayton D and Hills M (1993) Statistical Models in Epidemiology. Oxford University Press: Oxford
6. Colman M, Easton DF, Horwich A and Peckham MJ (1988) Second malignancies and Hodgkin's disease - The Royal Marsden Hospital experience. Radiother Oncol 11: 229-238
7. Cox DR (1972) Regression models and life-tables. J R Stat Soc (B) 34: 187-202
8. Glicksman AS, Pajak TF, Gottlieh A, Nissen N, Stutzman L and Cooper MR (1982) Second malignant neoplasms in patients successfully treated for Hodgkin's disease: a Cancer and Leukemia Group B Study. Cancer Treatment Rep 66: 1035-1044
9. Hancock SL, Tucker MA and Hoppe RT (1993) Breast cancer after treatment of Hodgkin's disease. J Natl Canter Inst 85: 25-31
10. Henri-Amar M on behalf of the International Database on Hodgkin's Disease (IDHD) (1992) Second cancer after the treatment for Hodgkin's disease: a report from the International Database on Hodgkin's Disease. Ann Oncol 3 (Suppl. 4): S117-S128
11. Henri-Amar M, Pellae-Cosset B, Bayle-Weisgerber C, Hayat M, Cosset JM, Carde P and Tubiana M (1989) Risk of secondary acute leukemia and preleukemia after Hodgkin's disease: the Institut Gustave-Roussy experience. Recent Results Cancer Res 117: 270-283
12. Kaldor JM, Day NE, Band P, Choi NW, Clarke EA, Coleman MP, Hakama M, Koch M, Langmark F, Neal FE, Pettersson F, Pompe-Kirn V, Prior P and Storm H (1987) Second malignancies following testicular cancer, ovarian cancer and Hodgkin's disease: an international collaborative study among cancer registries. Int J Cancel 39: 571-585
13. Kaldor JM, Day NE, Clarke EA, Van Leeuwen FE, Henry-Amar M, Fiorentino MV, Bell J, Pedersen D, Band P, Assouline D, Koch M, Choi W, Prior P, Blair V, Langmark F, Kirn VP, Neal F, Peters D, Pfeiffer R, Karjalainen S, Cuzick J, Sutcliffe SB, Somers R, Pellac-Cosset B, Pappagallo GL, Fraser P, Storm H and Storall M (1990) Leukemia following Hodgkin's disease. N Engl J Med 322: 7-13
14. Kaldor JM, Day NE, Bell J, Clarke EA, Langmark F, Karjalainen S, Band P, Pedersen D, Choi W, Blair V, Henri-Amar M, Prior P, Assouline D, Pompe-Kirn V, Cartwright RA, Koch M, Arslan A, Fraser P, Sutcliffe SB, Host H, Hakama M and Storall M. (1992) Lung cancer following Hodgkin's disease: a case-control study. Int J Cancer 52: 677-681
15. Kaplan EL and Meier P (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481
16. National Research Council (1990) Health Effects of Exposure to Low Levels of Ionizing Radiation. BEIR V. National Academy Press: Washington DC
17. Pedersen-Bjegaard J, Specht L, Larsen SO, Ersbøll J, Struck J, Hansen MM, Hansen HH, Nissen NI (1987) Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy. Lancet 2: 83-88
18. Selby P, Patel P, Milan S, Meldrum M, Mansi J, Mbidde E, Brada M, Perren T, Forgeson G, Gore M, Smith I and McElwain T (1990) ChLVPP combination chemotherapy for Hodgkin's disease: long term results. Br J Cancer 62: 279-285
19. Sont JK, van Stiphout WAHJ, Noordijk EM, Molenaar J, Zwetsloot-Schonk JHM, Willemze R and Vandenbroucke JP (1992) Increased risk of second cancers in managing Hodgkin's disease: the 20-year Leiden experience. Ann Hematol 65: 213-218
20. Swerdlow AJ, Douglas AJ, Vaughan Hudson G, Vaughan Hudson B, Bennett MH and MacLennan KA (1992) Risk of second primary cancers after Hodgkin's disease by type of treatment: analysis of 2846 patients in the British National Lymphoma Investigation. Br Med J 304: 1137-1143
21. Swerdlow AJ, Douglas AJ, Vaughan Hudson G, Vaughan Hudson B and MacLennan KA (1993) Risk of second primary cancer after Hodgkin's disease in patients in the British National Lymphoma Investigation: relationships to host factors, histology and stage of Hodgkin's disease, and splenectomy. Br J Cancer 68: 1006-1011
22. Tucker MA, Coleman CN, Cox RS, Varghese A and Rosenberg SA (1988) Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med 318: 76-81
23. Van der Velden JW, van Putten WLJ, Guinee VF, Pfeiffer R, van Leeuwen FE, van der Linden EAM, Vardomskaya I, Lane W, Durand M, Lagarde C, Hagemeister FB, Hagenbeek A and Eghbali H (1988) Subsequent development of acute non-lymphocytic leukemia in patients treated for Hodgkin's disease. Int J Cancer 42: 252-255
24. Van Leeuwen FE, Klokman WJ, Hagenbeek A, Noyon R, van den Belt-Dusebout AW, van Kerkhoff EHM, van Heerde P and Somers R (1994a) Second cancer risk following Hodgkin's disease: a 20-year follow-up study. J Clin Ontol 12: 312-325
25. Van Leeuwen FE, Chorus AMJ, van den Belt-Dusebout AW, Hagenbeek A, Noyon R, van Kerkhoff EHM, Pinedo HM and Somers R (1994b) Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. J Clin Oncol 12: 1063-1073
26. World Health Organization (1978) Manual of the International Statistical Classification of Diseases, Injuries, and Causes of Death. WHO: Geneva
27. Young RC, Bookman MA, Longo DL (1990) Late complications of Hodgkin's disease management. J Natl Cancer Inst Monogr 10: 55-60